---
document_datetime: 2025-12-29 12:24:56
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ibrance.html
document_name: ibrance.html
version: success
processing_time: 0.102619
conversion_datetime: 2025-12-29 23:21:47.146798
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ibrance

[RSS](/en/individual-human-medicine.xml/66925)

##### Authorised

This medicine is authorised for use in the European Union

palbociclib Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ibrance](#news-on)
- [Related information](#related-information-826)
- [More information on Ibrance](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Ibrance is a cancer medicine used to treat breast cancer when the cancer is locally advanced (has spread nearby) or metastatic (has spread to other parts of the body). Ibrance can only be used when the cancer cells have receptors (targets) for certain hormones on their surface (HR-positive) and do not produce abnormally large quantities of a receptor called HER2 (HER [human epidermal growth factor] negative). Ibrance is used in the following ways:

- together with an aromatase inhibitor (a hormonal medicine for cancer);
- together with fulvestrant (another hormonal medicine for cancer) in patients who have previously been treated with a hormonal medicine.

In women who have not yet reached menopause, a medicine called a luteinising hormone-releasing hormone agonist should also be given.

Ibrance contains the active substance palbociclib.

Expand section

Collapse section

## How is Ibrance used?

Ibrance can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the use of cancer medicines.

Ibrance is available as capsules and tablets (75 mg, 100 mg and 125 mg). The recommended dose is 125 mg once a day for 21 consecutive days, followed by a 7-day break to complete a 28-day treatment cycle. Treatment should be taken at around the same time each day. The capsules should be taken with food while the tablets can be taken with or without food. Treatment should continue for as long as the patient is benefitting from it and side effects are tolerable. If the patient experiences certain side effects, treatment may need to be interrupted or stopped, or the dose reduced.

For more information about using Ibrance, see the package leaflet or contact your doctor or pharmacist.

## How does Ibrance work?

The active substance in Ibrance, palbociclib, blocks the activity of enzymes known as cyclin-dependent kinases (CDK) 4 and 6, which play a key role in regulating the way cells grow and divide. In some cancers, including HR-positive breast cancer, the activity of CDK 4 and 6 is increased, which helps the cancer cells to multiply uncontrollably. By blocking CDK4 and CDK6, Ibrance slows the growth of HR-positive breast cancer cells.

## What benefits of Ibrance have been shown in studies?

Ibrance has been studied in two main studies of women with HR-positive, HER2-negative breast cancer. In both studies, the main measure of effectiveness was how long patients lived without their disease getting worse (progression-free survival).

The first study involved 521 women with metastatic breast cancer that had got worse after treatment with a hormonal medicine. They received either Ibrance and fulvestrant or a placebo (dummy medicine) and fulvestrant. Women taking Ibrance and fulvestrant lived on average 11.2 months without their disease getting worse compared with 4.6 months for women taking placebo and fulvestrant.

The second study involved 666 women who had been through the menopause and whose breast cancer had started to spread and who had not yet received cancer treatment. They received either Ibrance and letrozole (an aromatase inhibitor) or placebo and letrozole. Women taking Ibrance and letrozole lived on average 24.8 months without their disease getting worse compared with 14.5 months for women taking placebo and letrozole.

## What are the risks associated with Ibrance?

The most common side effects with Ibrance (which may affect more than 1 in 5 people) are neutropenia (low blood levels of neutrophils, a type of white blood cell that fights infection), infections, leucopenia (low white blood cell counts), tiredness, nausea (feeling sick), stomatitis (inflammation of the lining of the mouth), anaemia (low red blood cell counts), diarrhoea, alopecia (hair loss) and thrombocytopenia (low blood platelet counts).

The most common severe side effects with Ibrance (which may affect up to 1 in 50 people) are neutropenia, leucopenia, infections, anaemia, tiredness and increased blood levels of liver enzymes (aspartate and alanine transaminases).

For the full list of side effects of Ibrance, see the package leaflet.

Ibrance must not be used by patients who are taking St John's wort (a herbal preparation used to treat depression). For the full list of restrictions, see the package leaflet.

## Why is Ibrance authorised in the EU?

Ibrance has been shown to prolong the time patients live without their disease getting worse by an average of 6 to 10 months, which is considered of clear clinical value. Regarding safety, the main risk is neutropenia, which is a well-known risk of many cancer medicines and is considered manageable.

The European Medicines Agency therefore decided that Ibrance's benefits are greater than its risks and that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Ibrance?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ibrance have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Ibrance are continuously monitored. Side effects reported with Ibrance are carefully evaluated and any necessary action taken to protect patients.

## Other information about Ibrance

Ibrance received a marketing authorisation valid throughout the EU on 9 November 2016.

Ibrance : EPAR - Summary for the public

English (EN) (146.66 KB - PDF)

**First published:** 25/11/2016

**Last updated:** 06/03/2020

[View](/en/documents/overview/ibrance-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-291)

български (BG) (169.76 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

06/03/2020

[View](/bg/documents/overview/ibrance-epar-summary-public_bg.pdf)

español (ES) (145.26 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

06/03/2020

[View](/es/documents/overview/ibrance-epar-summary-public_es.pdf)

čeština (CS) (167.42 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

06/03/2020

[View](/cs/documents/overview/ibrance-epar-summary-public_cs.pdf)

dansk (DA) (144.32 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

06/03/2020

[View](/da/documents/overview/ibrance-epar-summary-public_da.pdf)

Deutsch (DE) (147.84 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

06/03/2020

[View](/de/documents/overview/ibrance-epar-summary-public_de.pdf)

eesti keel (ET) (133.53 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

06/03/2020

[View](/et/documents/overview/ibrance-epar-summary-public_et.pdf)

ελληνικά (EL) (172.29 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

06/03/2020

[View](/el/documents/overview/ibrance-epar-summary-public_el.pdf)

français (FR) (145.77 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

06/03/2020

[View](/fr/documents/overview/ibrance-epar-summary-public_fr.pdf)

hrvatski (HR) (166.98 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

06/03/2020

[View](/hr/documents/overview/ibrance-epar-summary-public_hr.pdf)

italiano (IT) (143.81 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

06/03/2020

[View](/it/documents/overview/ibrance-epar-summary-public_it.pdf)

latviešu valoda (LV) (178.45 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

06/03/2020

[View](/lv/documents/overview/ibrance-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (168.78 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

06/03/2020

[View](/lt/documents/overview/ibrance-epar-summary-public_lt.pdf)

magyar (HU) (167.23 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

06/03/2020

[View](/hu/documents/overview/ibrance-epar-summary-public_hu.pdf)

Malti (MT) (177.77 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

06/03/2020

[View](/mt/documents/overview/ibrance-epar-summary-public_mt.pdf)

Nederlands (NL) (144.51 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

06/03/2020

[View](/nl/documents/overview/ibrance-epar-summary-public_nl.pdf)

polski (PL) (171.3 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

06/03/2020

[View](/pl/documents/overview/ibrance-epar-summary-public_pl.pdf)

português (PT) (145.6 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

06/03/2020

[View](/pt/documents/overview/ibrance-epar-summary-public_pt.pdf)

română (RO) (167.35 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

06/03/2020

[View](/ro/documents/overview/ibrance-epar-summary-public_ro.pdf)

slovenčina (SK) (167.32 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

06/03/2020

[View](/sk/documents/overview/ibrance-epar-summary-public_sk.pdf)

slovenščina (SL) (165.95 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

06/03/2020

[View](/sl/documents/overview/ibrance-epar-summary-public_sl.pdf)

Suomi (FI) (143.17 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

06/03/2020

[View](/fi/documents/overview/ibrance-epar-summary-public_fi.pdf)

svenska (SV) (144.39 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

06/03/2020

[View](/sv/documents/overview/ibrance-epar-summary-public_sv.pdf)

Ibrance : EPAR - Risk management plan

English (EN) (2.38 MB - PDF)

**First published:** 18/09/2024

[View](/en/documents/rmp/ibrance-epar-risk-management-plan_en.pdf)

## Product information

Ibrance : EPAR - Product Information

English (EN) (927.11 KB - PDF)

**First published:** 25/11/2016

**Last updated:** 07/03/2025

[View](/en/documents/product-information/ibrance-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-697)

български (BG) (673.8 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

07/03/2025

[View](/bg/documents/product-information/ibrance-epar-product-information_bg.pdf)

español (ES) (677.9 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

07/03/2025

[View](/es/documents/product-information/ibrance-epar-product-information_es.pdf)

čeština (CS) (717.79 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

07/03/2025

[View](/cs/documents/product-information/ibrance-epar-product-information_cs.pdf)

dansk (DA) (601.94 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

07/03/2025

[View](/da/documents/product-information/ibrance-epar-product-information_da.pdf)

Deutsch (DE) (676.65 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

07/03/2025

[View](/de/documents/product-information/ibrance-epar-product-information_de.pdf)

eesti keel (ET) (606.36 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

07/03/2025

[View](/et/documents/product-information/ibrance-epar-product-information_et.pdf)

ελληνικά (EL) (669.45 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

07/03/2025

[View](/el/documents/product-information/ibrance-epar-product-information_el.pdf)

français (FR) (680.38 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

07/03/2025

[View](/fr/documents/product-information/ibrance-epar-product-information_fr.pdf)

hrvatski (HR) (739.57 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

07/03/2025

[View](/hr/documents/product-information/ibrance-epar-product-information_hr.pdf)

íslenska (IS) (895.51 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

07/03/2025

[View](/is/documents/product-information/ibrance-epar-product-information_is.pdf)

italiano (IT) (916.05 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

07/03/2025

[View](/it/documents/product-information/ibrance-epar-product-information_it.pdf)

latviešu valoda (LV) (825.26 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

07/03/2025

[View](/lv/documents/product-information/ibrance-epar-product-information_lv.pdf)

lietuvių kalba (LT) (647.14 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

07/03/2025

[View](/lt/documents/product-information/ibrance-epar-product-information_lt.pdf)

magyar (HU) (721.96 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

07/03/2025

[View](/hu/documents/product-information/ibrance-epar-product-information_hu.pdf)

Malti (MT) (753.34 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

07/03/2025

[View](/mt/documents/product-information/ibrance-epar-product-information_mt.pdf)

Nederlands (NL) (633.01 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

07/03/2025

[View](/nl/documents/product-information/ibrance-epar-product-information_nl.pdf)

norsk (NO) (648.82 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

07/03/2025

[View](/no/documents/product-information/ibrance-epar-product-information_no.pdf)

polski (PL) (617.09 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

07/03/2025

[View](/pl/documents/product-information/ibrance-epar-product-information_pl.pdf)

português (PT) (634.73 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

07/03/2025

[View](/pt/documents/product-information/ibrance-epar-product-information_pt.pdf)

română (RO) (668.65 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

07/03/2025

[View](/ro/documents/product-information/ibrance-epar-product-information_ro.pdf)

slovenčina (SK) (718.13 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

07/03/2025

[View](/sk/documents/product-information/ibrance-epar-product-information_sk.pdf)

slovenščina (SL) (678.88 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

07/03/2025

[View](/sl/documents/product-information/ibrance-epar-product-information_sl.pdf)

Suomi (FI) (2.05 MB - PDF)

**First published:**

25/11/2016

**Last updated:**

02/04/2025

[View](/fi/documents/product-information/ibrance-epar-product-information_fi.pdf)

svenska (SV) (1006.83 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

07/03/2025

[View](/sv/documents/product-information/ibrance-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000253412 06/03/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ibrance : EPAR - All Authorised presentations

English (EN) (32.3 KB - PDF)

**First published:** 25/11/2016

**Last updated:** 10/01/2022

[View](/en/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-403)

български (BG) (36.26 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/bg/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_bg.pdf)

español (ES) (31.37 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/es/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_es.pdf)

čeština (CS) (32.68 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/cs/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (32 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/da/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (32.82 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/de/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (33.13 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/et/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (33.62 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/el/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_el.pdf)

français (FR) (30.54 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/fr/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (32.22 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/hr/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (30.63 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/is/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_is.pdf)

italiano (IT) (32.76 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/it/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (33.9 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/lv/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (33.1 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/lt/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (32.38 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/hu/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (32.77 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/mt/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (30.05 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/nl/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (32.98 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/no/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_no.pdf)

polski (PL) (32.93 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/pl/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_pl.pdf)

português (PT) (30.11 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/pt/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_pt.pdf)

română (RO) (31.84 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/ro/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (33.99 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/sk/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (31.11 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/sl/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (30.51 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/fi/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (30.32 KB - PDF)

**First published:**

25/11/2016

**Last updated:**

10/01/2022

[View](/sv/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ibrance Active substance Palbociclib International non-proprietary name (INN) or common name palbociclib Therapeutic area (MeSH) Breast Neoplasms Anatomical therapeutic chemical (ATC) code L01EF01

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Ibrance is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer:

- in combination with an aromatase inhibitor;
- in combination with fulvestrant in women who have received prior endocrine therapy.

In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.

## Authorisation details

EMA product number EMEA/H/C/003853 Marketing authorisation holder

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

Opinion adopted 15/09/2016 Marketing authorisation issued 09/11/2016 Revision 24

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ibrance : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (144.65 KB - PDF)

**First published:** 07/03/2025

[View](/en/documents/procedural-steps-after/ibrance-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Ibrance : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (176.07 KB - PDF)

**First published:** 17/01/2017

**Last updated:** 07/03/2025

[View](/en/documents/procedural-steps-after/ibrance-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Ibrance-PAM-0000250384 : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-1902684

English (EN) (394.1 KB - PDF)

**First published:** 03/06/2025

[View](/en/documents/variation-report/ibrance-pam-0000250384-epar-assessment-report_en.pdf)

Ibrance-H-C-003853-P46-006 : EPAR - Assessment report

Adopted

Reference Number: EMA/341000/2024

English (EN) (1.15 MB - PDF)

**First published:** 22/07/2024

[View](/en/documents/variation-report/ibrance-h-c-003853-p46-006-epar-assessment-report_en.pdf)

Ibrance-H-C-PSUSA-00010544-202308 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/107553/2024

English (EN) (94.24 KB - PDF)

**First published:** 22/05/2024

[View](/en/documents/scientific-conclusion/ibrance-h-c-psusa-00010544-202308-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Ibrance-H-C-PSUSA-00010544-202008 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

English (EN) (202.95 KB - PDF)

**First published:** 03/06/2021

**Last updated:** 06/06/2023

[View](/en/documents/scientific-conclusion/ibrance-h-c-psusa-00010544-202008-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Ibrance : EPAR - Public assessment report

Adopted

Reference Number: EMA/652627/2016

English (EN) (4.16 MB - PDF)

**First published:** 25/11/2016

**Last updated:** 25/11/2016

[View](/en/documents/assessment-report/ibrance-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ibrance

Adopted

Reference Number: EMA/CHMP/597497/2016

English (EN) (73.62 KB - PDF)

**First published:** 16/09/2016

**Last updated:** 16/09/2016

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ibrance_en.pdf)

#### News on Ibrance

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2016 (corrected)](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2016-corrected) 21/09/2016

[New treatment for breast cancer](/en/news/new-treatment-breast-cancer) 16/09/2016

#### Related information

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC0038530000) (initial marketing authorisation)

#### More information on Ibrance

- [EMEA-002146-PIP01-17-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002146-pip01-17-m04)
- [EMEA-002146-PIP02-18 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002146-pip02-18)
- [Observational multicentric national longitudinal study evaluating Ibrance (palbociclib) in a real life setting conditions in patients 70 years old and older presenting a locally advanced or metastatic HR+/HER2- breast cancer (PalomAGE) - post-authorisation study](https://catalogues.ema.europa.eu/study/41239)
- [\"Palbociclib plus Aromatase- inhibitor as first-line treatment for Hormone Receptor (HR)-positive /Human Epidermal Growth Factor Receptor 2 (HER2)-negative locally advanced or metastatic breast cancer patients in Italy: a retrospective observational study (Palbo-Italy)\" - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000352)
- [Descriptive Analyses of Clinical Characteristics and Treatment Patterns of Breast Cancer Patients Initiating Palbociclib (Ibrance®) Treatment in the US Community Oncology Setting - post-authorisation study](https://catalogues.ema.europa.eu/study/18408)
- [Real-World Treatment Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor as First Line Therapy in Post-Menopausal Women and Men With Metastatic Breast Cancer (P-REALITY 3) - post-authorisation study](https://catalogues.ema.europa.eu/study/41804)
- [Safety of Palbociclib Among Breast Cancer Patients in the United States - post-authorisation study](https://catalogues.ema.europa.eu/study/35998)
- [Retrospective Assessment of Treatment Patterns and Outcomes Associated with Palbociclib in Combination With Letrozole in Postmenopausal Women With HR+/HER2- Advanced Breast Cancer - post-authorisation study](https://catalogues.ema.europa.eu/study/26344)
- [Understanding Early and Ongoing Treatment Utilization of Palbociclib in a US Community Oncology Setting - post-authorisation study](https://catalogues.ema.europa.eu/study/18421)
- [Prospective Observational Study of Mobile App-Based Patient-Reported Outcomes in Advanced Breast Cancer (MADELINE) - post-authorisation study](https://catalogues.ema.europa.eu/study/39939)
- [Prospective Observational Study of Mobile App-Based Patient-Reported Outcomes in Advanced Breast Cancer in Asia (MADELINE ASIA) - post-authorisation study](https://catalogues.ema.europa.eu/study/50391)
- [Treatment patterns and clinical effectiveness outcomes of palbociclib in combination with aromatase inhibitor (AI) or fulvestrant in hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer patients: an observational study using Flatiron Electronic Health Record (EHR) database - post-authorisation study](https://catalogues.ema.europa.eu/study/21046)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 03/06/2025

## Share this page

[Back to top](#main-content)